glp-1 obesity drug news october 21 2025 Americans Need More Information About Weight Loss Drugs GLP-1 Weight-Loss Drugs Ride Health,

K., Renzi, G., & Olek, R

Lancet Neurol 14(3):329340 Biessels GJ, Verhagen C, Janssen J et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial

Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018-2030 (USD Million) 7.5

We included original research studies, clinical trials, review articles, and relevant commentaries that addressed the efficacy, safety, therapeutic potential, or emerging innovations of GLP-1RAs

Introduction Despite major advance in treatment, cardiovascular diseases are still one of the leading causes of mortality and morbidity in the world

Tirzepatide has received approval for use in patients with T2D following several phase 3 studies testing and demonstrating its marked anti-hyperglycemic efficacy and positive actions on multiple cardiovascular risk factors, associated with an excellent safety profile [2, 3]